After several names in the Canadian cannabis space invested early into Australia, some firms are choosing to adjust their plans with respect to the country’s burgeoning medical marijuana sector.

In the past two weeks, Canopy Growth (NYSE:CGC,TSX:WEED), Cronos Group (NASDAQ:CRON,TSX:CRON) and Aphria (NYSE:APHA,TSX:APHA) all announced a significant change in plans for their Australian operations. Aphria’s was the most recent, coming on Wednesday (October 23).

Aphria is reportedly looking to sell 37 million shares of its minority stake in Australian cannabis producer Althea Group Holdings (ASX:AGH), according to a report from Australian Financial Review.

How does the cannabis market fare in Australia? Read our FREE outlook report on Australian cannabis investing!

Get an in depth market report for free!

The Ontario-based company has a total of 50.1 million shares, representing a 25 percent ownership stake in Althea.

Aphria originally invested C$2.5 million in the Melbourne cannabis firm back in 2018, allowing Aphria to sell marijuana products into Australia’s medical cannabis space.

In 2018, Althea received cultivation and manufacturing licenses and also launched its initial public offering (IPO) to list on the Australian Securities Exchange (ASX).

Cannabis giant Canopy Growth also announced it was divesting its stake in an Australia-based marijuana company.

Canopy Growth confirmed the sale of its 13.2 percent interest in AusCann Group Holdings (ASX:AC8), or over 42 million shares, ending the three-year relationship between the two firms. The company came away with C$6.3 million from the sale.

“The decision to divest our position in AusCann … will allow us to sharpen our focus on our wholly-owned operations in the market, while continuing to collaborate with our partners at AusCann,” Canopy Growth CEO Mark Zekulin said in the press release.

Cronos Group will split up with its Australian division by way of a new listing. Cronos Australia, a joint venture with NewSouthern Capital, plans to issue 40 million shares at AU$0.50 a piece ahead of its listing on the ASX, where it expects to list by November 11.

Like Aphria, Cronos plans on helping its Australian counterpart develop its position in the Australian cannabis landscape, according to Cronos Chairman and CEO Mike Gorenstein.

In a prospectus for the proposed company, it is noted that Cronos Australia seeks to lead the health and wellness space in the Asia-Pacific region, which will include export opportunities to New Zealand, though the distribution of tetrahydrocannabinol and cannabidiol products.

Medical marijuana was first legalized in the country in 2016 and since then the sector has grown. A report from Prohibition Partners projected medical cannabis in the country could be worth up to US$2.1 billion by 2028. In September, the Australian Capital Territory became the first region in Australia to fully legalize the recreational use of marijuana.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Which Australian stocks are worth your investment? What do experts forecast for the Australian stock market? Read our FREE outlook report to learn more!

Get an in depth market report for free!

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less